OPEN-LABEL PHASE I/II CAMPATH-1H IN ACTIVE REFRACTORY RHEUMATOID ARTHRITIS

开放标签 I/II 期 CAMPATH-1H 用于治疗活动性难治性类风湿关节炎

• 批准号: 3738853
• 负责人: EUGENE W ST CLAIR
• 金额: --
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3738853
• 关键词: CD antigens; antiarthritic agent; clinical trials; drug screening /evaluation; helper T lymphocyte; human subject; human therapy evaluation; immunopathology chemotherapy; immunotherapy; leukocyte count; monoclonal antibody; rheumatoid arthritis

The purpose of this study is to provide long-term safety monitoring for patients with rheumatoid arthritis that have been previously treated with CAMPATH-1H, a potent T cell-depleting monoclonal antibody. These patients will continue to be followed until their CD4+ T cell counts remain consistently above 200 cells/mm3.

本研究的目的是提供长期的安全监测 曾接受过药物治疗的类风湿关节炎患者 CAMPATH-1H，一种高效的T细胞耗竭单抗。这些 患者将继续接受跟踪，直到他们的CD4+T细胞计数 始终保持在200个电池/mm3以上。